# COMBINED MODALITIES:  RADIOTHERAPY AND CHEMOTHERAPY

> **NIH NIH R01** · STANFORD UNIVERSITY · 1991 · $192,699

## Abstract

The longterm objectives of this radiobiological study are centered
upon finding combinations of radiation with cytotoxic drugs whose
effects are superior to those of the constituent modalities alone
or of their algebraic sums.  There are 10 specific aims which
include:  To investigate schedule dependence for combinations of
cis-dichlordiammine platinum II (c-DDP) and radiation, examining
different fractionated radiation courses; to determine whether the
addition of 5-FU to c-DDP and radiation can enhance therapeutic
effect as a function of sequence and schedule; to investigate
schedule dependence for combinations of cyclophosphamide (CY) with
fractionated irradiation; to investigate whether specific electron-
affinic sensitizers can further enhance optimal c-DDP and CY
radiation combinations; to investigate the effectiveness of
radiation combined with multiple drug regimens; to confirm the
correlation between breathing rate and pulmonary fibrosis by
studying post-treatment fibrogenesis; to investigate the kinetics
of cell death in tumor cells by time lapse cinemicrography; to
further define the protective effect of Interleukin-1 (IL-1)
against whole body radiation lethality; to investigate protective
effect of IL-1 against CY lethality; to investigate whether IL-1
affects the sensitivity of normal tissues other than the bone
marrow, viz. intestinal mucosa; and to determine whether IL-I can
improve the therapeutic effectiveness of chemotherapy/radiotherapy
combinations.  All experiments will be done in inbred SPF mice
either with syngeneic tumors (RIF-I, SCCVII, EMT6, KHT) or on
normal tissues.  Tumor response will be assessed primarily by
regrowth delay; lung response primarily by breathing rate; and
intestinal response primarily by crypt survival.  This health-
related project is directly applicable to human cancer therapy.

## Key facts

- **NIH application ID:** 3172260
- **Project number:** 5R01CA034544-08
- **Recipient organization:** STANFORD UNIVERSITY
- **SAM.gov UEI:** HJD6G4D6TJY5
- **Principal Investigator:** ROBERT FRIEND KALLMAN
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 1991
- **Award amount:** $192,699
- **Award type:** 5
- **Project period:** 1983-05-01 → 1992-11-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/3172260

## Citation

> US National Institutes of Health, RePORTER application 3172260, COMBINED MODALITIES:  RADIOTHERAPY AND CHEMOTHERAPY (5R01CA034544-08). Retrieved via MORVS 2026-10-25 from https://api.morvs.ai/grant/nih/3172260. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*